ALG8 Activators
ALG8 can facilitate its enzymatic function through various biochemical mechanisms. Uridine 5'-diphospho-N-acetylglucosamine (UDP-GlcNAc) serves as a direct substrate for ALG8, providing the glucose residues that ALG8 transfers during the assembly of lipid-linked oligosaccharides. This assembly is a critical step in the N-linked glycosylation pathway, and the presence of UDP-GlcNAc ensures that ALG8 has a consistent supply of glucose moieties for its activity. Similarly, dolichol phosphate is a lipid carrier molecule that plays an integral role in the N-linked glycosylation process. ALG8 interacts with dolichol phosphate within the ER membrane, adding glucose residues to the growing oligosaccharide chain. This interaction is crucial for the proper function of ALG8, and the addition of these glucose residues is a necessary step in the maturation of glycoproteins.
Magnesium chloride and manganese(II) chloride provide divalent cations, Mg2+ and Mn2+, which are necessary cofactors for ALG8 activation. These ions facilitate the enzyme's activity by stabilizing the formation of the UDP-GlcNAc and dolichol phosphate complex, thereby enhancing the transfer of glucose by ALG8. On the other hand, glycosyltransferase inhibitors such as N-Butyldeoxynojirimycin, 1-Deoxynojirimycin, castanospermine, deoxymannojirimycin, swainsonine, kifunensine, and nojirimycin can lead to an increase in the pool of oligosaccharide substrates available to ALG8. By inhibiting competing enzymes within the glycosylation pathway, these inhibitors indirectly lead to an accumulation of substrates that require further modification by ALG8. For instance, swainsonine and kifunensine inhibit specific mannosidases, thereby allowing an increased concentration of mannose-rich oligosaccharides, which are substrates for ALG8. Furthermore, Brefeldin A disrupts Golgi apparatus function, causing a buildup of glycosylation intermediates in the ER. This accumulation indirectly ensures a higher concentration of available substrates for ALG8 activity, facilitating the glucose addition process that is essential for glycoprotein synthesis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Glutathione, reduced | 70-18-8 | sc-29094 sc-29094A | 10 g 1 kg | $82.00 $2091.00 | 8 | |
Uridine 5'-diphospho-N-acetylglucosamine (UDP-GlcNAc) serves as a substrate for ALG8, which is involved in the glycosylation pathway specifically in the addition of glucose residues to dolichol-linked oligosaccharides. The presence of UDP-GlcNAc directly activates ALG8 by providing the necessary glucose moieties that ALG8 transfers in the assembly of the lipid-linked oligosaccharide, a precursor for N-linked glycosylation. | ||||||
Magnesium chloride | 7786-30-3 | sc-255260C sc-255260B sc-255260 sc-255260A | 10 g 25 g 100 g 500 g | $28.00 $35.00 $48.00 $125.00 | 2 | |
Magnesium chloride provides Mg2+ ions which are cofactors necessary for the activation of ALG8 enzymatic activity. Mg2+ ions stabilize the formation of the UDP-GlcNAc and dolichol phosphate complex, facilitating the transfer of glucose residues by ALG8 during the glycosylation process. | ||||||
Manganese(II) chloride beads | 7773-01-5 | sc-252989 sc-252989A | 100 g 500 g | $19.00 $31.00 | ||
Manganese(II) chloride provides Mn2+ ions which can act as essential cofactors for ALG8, similar to magnesium. Mn2+ ions are known to activate various enzymes by stabilizing substrate binding and enhancing catalytic activity, thus potentially enhancing ALG8 function in oligosaccharide assembly. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
1-Deoxynojirimycin, similar to N-Butyldeoxynojirimycin, may inhibit other glycosyltransferases leading to an increased pool of oligosaccharide substrates for ALG8, which could enhance the overall pathway flux and thereby functionally activate ALG8. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine is another glycosidase inhibitor that could lead to an accumulation of glycoprotein substrates for ALG8, potentially enhancing its activity by increasing the availability of substrates for the enzymatic reaction that ALG8 catalyzes in the glycosylation process. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin might similarly increase the substrate pool for ALG8 by inhibiting competing enzymes in the glycosylation pathway, indirectly leading to the functional activation of ALG8 as more substrate becomes available for its enzymatic activity. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits mannosidase II, which could lead to an increased concentration of the mannose-rich oligosaccharides that are substrates for ALG8, indirectly supporting the functional activation of ALG8 by increasing its substrate availability. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine is a mannosidase I inhibitor that could lead to an accumulation of high-mannose oligosaccharides, hence indirectly increasing the substrate for ALG8 and potentially enhancing its activity in the process of glycoprotein synthesis. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus function, which can lead to a buildup of glycosylation intermediates within the ER, including those acted upon by ALG8. This accumulation can indirectly activate ALG8 by increasing the concentration of substrates that require the addition of glucose residues. | ||||||